By determining the magnitude and quality of TCR and B-cell receptor (BCR) responses in T-PLL and CLL, respectively, mostly through a kinase-enhancing effect [24,26], TCL1A provides survival advantages through threshold-lowering effects in the context of dependence on low-level (tonic) antigen receptor input. This evidence concerns the gene TCL1A and B-cell chronic lymphocytic leukemia.